Mycobacterium tuberculosis ESAT 6 Protein EsxA : 파이프라인 리뷰

※ 본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

Mycobacterium tuberculosis ESAT 6 Protein EsxA를 표적으로 한 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등을 전해드립니다.

서론

• 조사 범위

Mycobacterium tuberculosis ESAT 6 Protein EsxA 개요

치료제 개발

• 개발중인 제품 : 개발 단계별
• 개발중인 제품 : 치료 영역별
• 개발중인 제품 : 증상별

파이프라인 제품 상황 개요

• 후기 단계 제품
• 초기 단계 제품

기업에서 개발중인 제품

대학/기관에서 개발중인 제품

치료제 평가

• 단독/병용 치료제
• 투여 경로별
• 분자 종류별

치료제 개발에 참여하고 있는 기업

• Inovio Pharmaceuticals, Inc.
• Lipotek Pty Ltd.
• Polymun Scientific Immunbiologische Forschung GmbH

약제 프로파일

주요 뉴스 및 프레스 릴리스

부록

도표

Summary:

Global Markets Direct's, 'Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Pipeline Review, H2 2016', provides in depth analysis on Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted pipeline therapeutics.

The report provides comprehensive information on the Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

• The report provides a snapshot of the global therapeutic landscape for Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA)
• The report reviews Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted therapeutics and enlists all their major and minor projects
• The report assesses Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted therapeutics

Reasons to buy:

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

• Table of Contents
  • List of Tables
  • List of Figures
• Introduction
  • Global Markets Direct Report Coverage
• Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) Overview
• Therapeutics Development
  • Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Products under Development by Stage of Development
  • Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Products under Development by Therapy Area
  • Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Products under Development by Indication
• Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Pipeline Products Glance
  • Late Stage Products
  • Early Stage Products
• Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Products under Development by Companies
• Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Products under Development by Universities/Institutes
• Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Therapeutics Assessment
  • Assessment by Monotherapy/Combination Products
  • Assessment by Route of Administration
  • Assessment by Molecule Type
• Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Companies Involved in Therapeutics Development
  • Inovio Pharmaceuticals, Inc.
  • Lipotek Pty Ltd.
  • Polymun Scientific Immunbiologische Forschung GmbH
• Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Drug Profiles
  • HG856-A - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • HG856-BCG - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • HG856-SeV - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • RSQ-15 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • SSIH-56IC31 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • TB/FLU-04L - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • tuberculosis vaccine - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • tuberculosis vaccine - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
• Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Featured News & Press Releases
  • Nov 08, 2013: Valneva: SSI and Aeras initiate Phase I/IIa Clinical Trial for Tuberculosis Vaccine Candidate Using IC31 Adjuvant
  • Jan 11, 2012: Intercell And Statens Serum Institut Progress Vaccine Clinical Development To Fight Tuberculosis
  • Dec 01, 2011: Vaccine Targeting Latent Tuberculosis Enters Clinical Testing
  • Jan 24, 2011: Researchers At Statens Serum Institut Develop New Vaccine With Dual Protection Against Tuberculosis
  • Jan 24, 2011: Researchers Develop New Vaccine With Dual Protection Against Tuberculosis
• Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

• Number of Products under Development for, H2 2016
• Number of Products under Development by Therapy Area, H2 2016
• Number of Products under Development by Indication, H2 2016
• Comparative Analysis by Late Stage Development, H2 2016
• Comparative Analysis by Early Stage Products, H2 2016
• Number of Products under Development by Companies, H2 2016
• Products under Development by Companies, H2 2016
• Number of Products under Investigation by Universities/Institutes, H2 2016
• Products under Investigation by Universities/Institutes, H2 2016
• Assessment by Monotherapy/Combination Products, H2 2016
• Number of Products by Stage and Route of Administration, H2 2016
• Number of Products by Stage and Molecule Type, H2 2016
• Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
• Pipeline by Lipotek Pty Ltd., H2 2016
• Pipeline by Polymun Scientific Immunbiologische Forschung GmbH, H2 2016

List of Figures

• Number of Products under Development for, H2 2016
• Comparative Analysis by Early Stage Products, H2 2016
• Assessment by Monotherapy/Combination Products, H2 2016
• Number of Products by Routes of Administration, H2 2016
• Number of Products by Stage and Routes of Administration, H2 2016
• Number of Products by Molecule Types, H2 2016
• Number of Products by Stage and Molecule Type, H2 2016